A two-month cisplatin-epirubicin-paclitaxel (PET) weekly administration is highly effective in large operable breast cancer. Final analysis of a SICOG phase II study

Maiorino, L.; Frasci, G.; D'Aiuto, G.; Comella, Pasquale; Thomas, R.; Bonito, Maurizio Di; Iodice, Giovanni; D’Aiuto, Massimiliano; Rubulotta, M. R.; Comella, G.

doi:10.1200/jco.2005.23.16_suppl.566

Search citation statements

Order By: Relevance

Paper Sections

Select...

The Role Of Taxanes1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2005

2006

Publication Types

Select...

Article4

Relationship

Self Cite0

Independent4

Authors

Journals

Cited by 4 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to these preliminary data, the weekly cisplatin, epirubicin and paclitaxel regimen can significantly improve the pCR rate when compared with standard 3-weekly administration. The role of weekly administration has been confirmed by recent trials [16,17].…”

Section: The Role Of Taxanesmentioning

confidence: 81%

Locally advanced breast cancer

Barni

Mandalà²

2006

Current Opinion in Obstetrics and Gynecology

View full text Add to dashboard Cite

show abstract

Section: The Role Of Taxanesmentioning

confidence: 81%

Locally advanced breast cancer

Barni

Mandalà²

2006

Current Opinion in Obstetrics and Gynecology

View full text Add to dashboard Cite

show abstract

Current treatment strategies in follicular lymphomas

Hiddemann¹,

Unterhalt²

2006

Annals of Oncology

View full text Add to dashboard Cite

Current management of follicular lymphomas

et al. 2006

View full text Add to dashboard Cite

SummaryAfter decades of stagnation, the prognosis of patients with follicular lymphomas (FL) has changed substantially within the last few years due to new and effective therapeutic modalities. These include myeloablative therapy followed by autologous stem cell transplantation (ASCT) in younger patients in first remission, which showed a significant prolongation of remission duration in three prospective randomised trials while the impact on overall survival still needs to be determined. Adding the anti-CD 20 antibody Rituximab to conventional chemotherapy resulted in a significant increase in remission rate, remission duration and, in two of four currently available prospective randomised studies, even in a longer overall survival. A prolongation of remission duration was also seen when Rituximab was given as maintenance after cytoreductive therapy including Rituximab. Radio-immunotherapy (RIT) with radioisotopes coupled to monoclonal antibodies produced encouraging data in several phase II studies. New therapeutic perspectives have also emerged from increasing insights into the biology of the disease that unravel molecular targets for novel agents, some of which have entered clinical evaluation already.

show abstract

A two-month cisplatin-epirubicin-paclitaxel (PET) weekly administration is highly effective in large operable breast cancer. Final analysis of a SICOG phase II study

Cited by 4 publications

References 0 publications

Locally advanced breast cancer

Locally advanced breast cancer

Current treatment strategies in follicular lymphomas

Current management of follicular lymphomas

Contact Info

Product

Resources

About